Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iSpecimen Inc. (ISPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. iSpecimen’s filings offer detailed information about its online marketplace for human biospecimens, its capital structure, financing activities, governance, and interactions with The Nasdaq Capital Market. Stock Titan enhances these documents with AI-powered summaries designed to explain the key points of each filing in clear language.
For investors and analysts reviewing annual reports on Form 10-K and quarterly reports on Form 10-Q, iSpecimen’s disclosures describe its mission to accelerate life science research through a global biospecimen marketplace, its technology platform, and its classification as an emerging growth company and smaller reporting company. These periodic reports, when available, are central sources for understanding the company’s business model, risk factors, and operating environment.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings include a November 21, 2025 report describing a Nasdaq notice that the company’s closing bid price had fallen below the $1.00 minimum required under Listing Rule 5550(a)(2), along with the timeframe provided to regain compliance. Other 8-Ks detail leadership changes, such as the appointment of a new Chief Executive Officer and the addition of an independent director, and report the results of a special meeting of stockholders where proposals related to a reverse stock split, an increase in authorized shares, private financing approvals, amendments to convertible securities, and an equity line of credit were approved.
Proxy statements on Schedule 14A (DEF 14A) shed light on corporate governance, director elections, stock incentive plans, and the agenda for annual and special meetings. The 2025 special meeting proxy statement outlines proposals to adjust the company’s capital structure and financing flexibility, while the 2025 annual meeting proxy statement covers director elections, auditor ratification, and a new stock incentive plan.
iSpecimen’s registration statements on Form S-1 and S-1/A describe offerings of common stock and pre-funded warrants, the use of proceeds, and detailed background on the company’s marketplace model. These filings also incorporate discussion of the company’s corporate treasury plan related to the Solana blockchain ecosystem and associated risk factors, as noted in the explanatory notes to recent amendments.
On Stock Titan, users can review these ISPC filings as they are updated in real time from EDGAR, while AI-generated overviews highlight important elements such as capital-raising terms, listing compliance matters, governance proposals, and structural changes to outstanding securities. This combination of source documents and AI explanations helps readers navigate complex forms, from 10-Ks and 10-Qs to 8-Ks, S-1 registration statements, and proxy materials, and track how iSpecimen manages its biospecimen marketplace business within the public-company regulatory framework.
iSpecimen Inc. (ISPC) called a special shareholder meeting to approve several capital actions. The Board seeks authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-100, with the exact ratio set at the Board’s discretion, primarily to support compliance with Nasdaq’s $1.00 minimum bid price. The Board also asks to increase authorized capital from 250,000,000 to 1,000,000,000 shares.
The agenda includes two Nasdaq Listing Rule 5635(d) approvals: one for potential non‑public financings exceeding 19.99% of outstanding common stock or voting power (at a price that may be below the Minimum Price), and another to permit an equity line of credit with issuances that could also exceed 19.99%. Separately, the company seeks to amend certain outstanding convertibles to raise the conversion price floor from 50% to 80% of the lowest VWAP during the applicable period, which may reduce shares issuable upon conversion. An adjournment proposal is also included.
The Board recommends voting FOR all proposals. The meeting is virtual on October 30, 2025 at 10:00 a.m. ET for holders of record as of July 25, 2025.
iSpecimen, Inc. filed an amended S-1 registration that describes a transactional biospecimen marketplace with concentrated revenue, recent capital raises, material liabilities, and operational and legal risks. The company reports its common shares outstanding prior to and after the offering are based on 8,211,156 shares as of
The company received a Nasdaq deficiency notice for minimum stockholders’ equity requirements and has submitted a compliance plan. Capital raises in 2024 included an ATM program that generated gross proceeds of approximately
iSpecimen, Inc. filed a preliminary revised proxy statement asking shareholders to approve a range of corporate actions at a Special Meeting. Key proposals include a reverse stock split selectable between 1-for-10 and 1-for-100, an increase in authorized shares, shareholder approval to permit issuances exceeding 19.99% under Nasdaq rules, amendments to a convertible floor, establishment of an equity line of credit (ELOC), and adjournment authority. The filing also discloses a planned corporate treasury program involving digital assets, retention of BlockArrow Capital as consultant, and an anticipated initial financing in Q4 2025 targeting at least $50 million and a longer-term objective of about $200 million over 12–24 months. The proxy explains voting mechanics, broker non-vote treatment, potential dilution, and risks tied to staking, locked Solana tokens, custodial and counterparty risks.
iSpecimen, Inc. (ISPC) amended its S-1 registration statement describing its business as a transactional biospecimen marketplace that sources remnant and research-use specimens from a global network of supply sites. The filing discloses specimen mix and supply-site counts (for example, ~44 clinical research centers, ~16 biorepositories, ~11 clinical lab sites, two blood donor centers and one cadaveric donation center as of December 31, 2024). Research-use biofluids and tissues represented ~49% and ~39% of revenue in 2024 and 2023, respectively, while one customer accounted for ~29% of 2024 revenue. The company disclosed a $1.0 million loan with an 18% note, capital raises including ~$1.49 million net ATM proceeds and a ~$5.0 million offering, capitalized software and sequenced-data intangible assets, an accumulated deficit, and material litigation and contract disputes (including a platform service disruption from January 25 to February 12, 2025). Nasdaq notified the company on June 4, 2025 of noncompliance with minimum stockholders’ equity and the company has submitted a compliance plan.
iSpecimen Inc. furnished an update on its strategic initiative to integrate digital assets into its business model. The company is pursuing plans to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since outlining this approach in August 2025, iSpecimen reports that several cryptocurrency-related companies have approached it with opportunities involving tokenized real-world assets and highly ranked cryptocurrencies. In parallel, the company continues meetings focused on developing the Solana-based treasury program. The update was provided via a press release, which is furnished for informational purposes and not deemed filed for liability purposes.
iSpecimen, Inc. (ISPC) operates a bioprocurement marketplace matching researchers with human specimens and associated data. The company reported concentrated, transactional revenue with research-use specimens (biofluids, tissues, cells) representing a substantial portion of sales and one customer accounting for ~29% of 2024 revenue. As of December 31, 2024 the company had $1.88 million cash and an accumulated deficit of ~$71.9 million. In 2024 the company raised capital through a $1.0 million short-term loan (18% interest), an ATM program that generated gross proceeds of ~$1.49 million (net ~$1.24 million), and an October 31, 2024 offering that produced gross proceeds of ~$4.998 million (net ~$4.632 million). The company completed a 1-for-20 reverse stock split in September 2024 and regained Nasdaq bid-price compliance. Material operational issues included a third-party platform disruption in January–February 2025 that temporarily shut the marketplace; related disputes and settlement activity are ongoing. The filing discloses significant customer concentration, nonrecurring transactional revenue, ongoing litigation and sales tax exposures, and efforts to reduce costs and capital needs.
iSpecimen Inc. reported that it has successfully completed Milestone 1 of its digital transformation program powered by Salestack Solutions. This first milestone covers installing the new Salestack platform and putting modern technology infrastructure in place.
With this foundation built, the company plans to move to Milestone 2, which will focus on integrating all parts of the business with the Salestack platform to improve operational efficiency, customer engagement, and data management across the organization.
iSpecimen Inc. (ISPC) filed an S-1 describing a marketplace that matches researchers with human biospecimens and related data. The company operates a technology-enabled bioprocurement marketplace that ingests and harmonizes supplier data, supports workflow and compliance, and sells a range of specimen products including remnant and research-use biofluids, tissues, and hematopoietic stem and immune cells.
Key facts disclosed include a 1-for-20 reverse stock split effective September 13, 2024; a $1.0 million short-term loan at 18% interest closed September 25, 2024; research-use specimens represented approximately 49% of revenue in 2024 (39% in 2023); one customer represented ~29% of revenue in 2024; the company reported an accumulated deficit and limited cash balances and has used debt and equity raises (including an ATM and a registered offering) to fund operations. The filing discloses litigation and a third-party platform outage in early 2025 that disrupted the marketplace and related settlement activity.
iSpecimen Inc. (ISPC) is soliciting votes for a virtual Special Meeting on September 26, 2025 at 10:00 a.m. ET to approve six proposals focused on capital structure and financing. The centerpiece is a board-authorized reverse stock split ranging from one-for-ten (1:10) to one-for-one hundred (1:100) intended to help meet Nasdaq's $1.00 minimum bid requirement. The board also seeks to increase authorized shares from 250,000,000 to 500,000,000, and to obtain shareholder approval under Nasdaq rules to permit future non-public financings and an equity line that may exceed 19.99% of outstanding stock. The company proposes to amend certain convertible securities to raise the conversion floor from 50% to 80% of VWAP, which may reduce shares issued on conversion. The proxy materials state a Record Date of July 25, 2025, note a 34% quorum, and list two different outstanding share counts in the filing (3,979,517 and 5,539,345), an inconsistency disclosed in the document. Proxy materials are available at proxyvote.com and distribution began on or about August 11, 2025.
FAQ
What is the current stock price of Ispecimen (ISPC)?
What is the market cap of Ispecimen (ISPC)?
